Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 775.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -219.88M |
| Shares Out | 60.53M |
| EPS (ttm) | -3.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 520,355 |
| Open | 13.40 |
| Previous Close | 13.25 |
| Day's Range | 12.69 - 13.60 |
| 52-Week Range | 5.68 - 16.74 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 30.13 (+135.21%) |
| Earnings Date | May 11, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $30.13, which is an increase of 135.21% from the latest price.
News
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and...
Cullinan Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Major milestones are expected in 2026 for two T-cell engager programs targeting autoimmune diseases and AML, with key data readouts and regulatory progress anticipated throughout the year. Enhanced trial enrollment, strong early efficacy, and a robust cash position support continued advancement.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline ...
Cullinan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Key milestones are expected in 2026, with pivotal data from CLN-978 in autoimmune diseases and CLN-049 in AML. Initial clinical data for CLN-978 in lupus and RA will be presented in Q2, with multi-dose RA data in Q3. CLN-049's promising efficacy supports broad expansion and potential accelerated approval.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
Multiple clinical catalysts are expected in 2026, including key data for CLN-978 in autoimmune diseases and CLN-049 in AML, with expansion into pivotal studies. Zipalertinib is advancing toward NDA submission and frontline study completion, supported by a strong financial position.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Multiple portfolio catalysts are expected in 2026, with key data readouts for T cell engagers in autoimmune diseases and AML. Strong clinical progress, robust financial runway, and strategic partnerships position the company for significant growth and value creation.
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommend...
Cullinan Therapeutics Transcript: Status Update
CLN-049, a FLT3-directed T-cell engager, shows robust efficacy and durable responses in relapsed/refractory AML, including TP53-mutated cases, with a favorable safety profile. Its broad applicability and regulatory progress position it for significant commercial and clinical impact.
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31...
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2...
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass.
Cullinan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Multiple pipeline catalysts are expected, with a focus on T-cell engagers for cancer and autoimmune diseases. CLN-049 shows promising response rates in AML, while CLN-978 is positioned to pioneer CD19 T-cell engager use in autoimmune indications, with strong financial runway.
Cullinan Therapeutics Transcript: Stifel 2025 Healthcare Conference
Multiple clinical programs are advancing, with a focus on T-cell engagers for autoimmune and oncology indications. Key data readouts are expected in 2026, and recent strategic moves, including program discontinuations and new acquisitions, have strengthened the pipeline and extended financial runway to 2029.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune disea...
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to b...
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate obse...
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a cl...
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
Taiho Oncology Inc. and Cullinan Therapeutics Inc. (NASDAQ:CGEM) shared new data on Sunday from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib for advanced...
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement co...
Cullinan Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum
The company is advancing a portfolio of oncology and autoimmune programs, with lead bispecific CLN-978 in phase 1 trials for SLE, RA, and Sjogren’s. Initial data for SLE and RA are expected in the first half of 2026. Recent protocol changes aim to boost enrollment, and financial runway extends into 2028.
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, tod...
Cullinan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Multiple clinical catalysts are expected in 2026, with a focus on CLN-978 for autoimmune diseases and zipolirenib for oncology. Strategic partnerships, strong cash reserves, and protocol amendments are driving accelerated development and broader market reach.